https://allsci.com/news/pipe-financing/aethlon-medical-merger-agrees-to-with-north/ AllScien 2026-09-17T17:23:30.834104Z North Immunology to go public via Aethlon reverse merger backed by USD 180m PIPE https://allsci.com/news/venture-financing/matisse-pharmaceuticals-secures-eur-14m-series-to/ AllScien 2026-09-17T15:50:29.605494Z Matisse secures EUR 14m Series A to advance isupartob sodium into Phase II sepsis trial https://allsci.com/news/licensing-and-partnerships/novo-nordisk-deal-orbis-secures-up-to-usd-14b-for/ AllScien 2026-09-17T15:41:51.824725Z Novo signs up for Orbis macrocycle platform in USD 1.4b deal https://allsci.com/news/clinical-trials/als-clinical-trial-acelot-begins-first-in-human/ AllScien 2026-09-17T14:44:33.881998Z Acelot takes TDP-43 ALS drug ACE-2223 into first-in-human trial https://allsci.com/news/approvals/kerendia-approval-fda-expands-bayers-to-type-1/ AllScien 2026-09-17T14:25:35.996784Z FDA expands Bayer’s Kerendia to type 1 diabetes-associated chronic kidney disease https://allsci.com/news/venture-financing/thyroid-eye-disease-sling-secures-usd-123m-to/ AllScien 2026-09-17T13:54:06.326894Z Sling secures USD 123m to advance oral TED drug linsitinib https://allsci.com/news/grants/male-contraceptive-weill-cornell-receives-207/ AllScien 2026-09-17T12:32:53.979312Z Weill Cornell wins USD 2.1m NIH grant to advance on-demand male contraceptive into Phase I https://allsci.com/news/clinical-trials/lunsumio-approval-roches-celestimo-win-supports/ AllScien 2026-09-17T11:02:56.600146Z Roche’s Lunsumio combination hits Phase III PFS goal in 2L+ follicular lymphoma https://allsci.com/news/licensing-and-partnerships/parkinsons-drug-sk-biopharmaceuticals-licenses/ AllScien 2026-09-17T10:41:15.603137Z SK Bio licenses Parkinson’s candidate 1ST-104 in USD 314.8m deal https://allsci.com/news/first-in-human-trials/ak158d1-clearance-akesos-receives-nmpa-phase-i/ AllScien 2026-09-17T10:19:38.996775Z Akeso’s EGFR/TROP2 bispecific ADC cleared for Phase I testing in China https://allsci.com/news/research/lung-cancer-immune-evasion-penn-preclinical-study/ AllScien 2026-09-17T09:37:48.506795Z UPenn study identifies NSD2–SETD2–EZH2 axis in KRAS lung cancer immunity https://allsci.com/news/licensing-and-partnerships/bispecific-adc-escugen-and-sovran-expand/ AllScien 2026-09-17T09:02:41.632736Z Escugen, Sovran pivot into co-development of pan-tumor bispecific MICA/B ADC https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-novo-expands-push-with/ AllScien 2026-09-17T08:49:59.498009Z Novo expands AI drug discovery push with Anthropic’s Claude Science collaboration https://allsci.com/news/venture-financing/circle-pharma-raises-usd-925m-to-advance-cid-165/ AllScien 2026-09-16T18:23:12.873332Z Circle Pharma raises USD 92.5m in Series E for cyclin D inhibitor https://allsci.com/news/research/human-cortical-organoids-stanford-researchers/ AllScien 2026-09-16T18:19:08.521694Z Stanford builds mice with human cortical tissue to model brain development https://allsci.com/news/clinical-trials/sky-0515-huntingtons-disease-skyhawks-posts/ AllScien 2026-09-16T17:59:25.873144Z Skyhawk’s SKY-0515 shows 1.59-point cUHDRS advantage at 15 months in Huntington’s disease https://allsci.com/news/pipe-financing/dry-eye-trial-cambium-bio-secures-aud-1085m-to/ AllScien 2026-09-16T17:07:29.459783Z Cambium Bio secures AUD 10.85m for Phase III of topical dry eye biologic https://allsci.com/news/licensing-and-partnerships/in-vivo-car-t-tempest-expands-strategy-with/ AllScien 2026-09-16T17:00:13.135436Z Tempest secures option on Senlang’s clinical-stage lentiviral in vivo CAR-T platform https://allsci.com/news/approvals/wakix-japan-approval-approves-viatris-for/ AllScien 2026-09-16T16:53:14.162174Z Japan approves Viatris’ Wakix for narcolepsy and OSAS-related daytime sleepiness https://allsci.com/news/licensing-and-partnerships/type-1-diabetes-elvinix-secures-exclusive-license/ AllScien 2026-09-16T16:25:57.444437Z Elvinix picks up Zealand's GLP-1/gastrin portfolio for type 1 diabetes development https://allsci.com/news/clinical-trials/iaso208-fda-clearance-bios-receives-ind-for/ AllScien 2026-09-16T15:26:07.884451Z IASO Bio’s CD20-targeted in vivo CAR-T cleared for US study in B-NHL https://allsci.com/news/research/resomelagon-dengue-who-identifies-synacts-as-the/ AllScien 2026-09-16T15:06:11.859578Z WHO review highlights SynAct’s resomelagon among six dengue drugs for further development https://allsci.com/news/venture-financing/traumatic-brain-injury-reemerge-exits-stealth/ AllScien 2026-09-16T14:35:47.443028Z ReEmerge exits stealth with USD 37m Series A to advance TBI brain stimulation study https://allsci.com/news/licensing-and-partnerships/sironax-novartis-deal-secures-usd-125m-as-takes/ AllScien 2026-09-16T13:59:08.104930Z Novartis exercises option to acquire Sironax blood-brain barrier delivery platform for USD 125m https://allsci.com/news/ipo-public-listing/sensorion-ipo-targets-potential-us-with/ AllScien 2026-09-16T13:45:21.233108Z Sensorion targets US IPO with SEC filing as it pivots to GJB2 gene therapy https://allsci.com/news/clinical-trials/linsitinib-trial-sling-starts-phase-iii-of-the/ AllScien 2026-09-16T13:29:39.658867Z Sling starts Phase III trial of oral TED therapeutic linsitinib https://allsci.com/news/licensing-and-partnerships/twist-bioscience-joins-lillys-tunelab-as/ AllScien 2026-09-16T13:21:25.740910Z Twist joins Lilly's TuneLab as preferred antibody characterization data provider https://allsci.com/news/regulatory/zumrad-eu-application-pfizer-withdraws-zumrads/ AllScien 2026-09-16T11:12:12.843386Z Pfizer follows AstraZeneca in pulling EU bladder cancer filing after CHMP concerns https://allsci.com/news/regulatory/sys6010-breakthrough-therapy-cspcs-secures-fourth/ AllScien 2026-09-16T10:43:36.102369Z China grants breakthrough status to CSPC’s EGFR ADC in AGA-negative NSCLC https://allsci.com/news/regulatory/zasocitinib-psoriasis-fda-grants-priority-review/ AllScien 2026-09-16T10:19:45.091592Z Takeda secures FDA Priority Review for oral TYK2 inhibitor zasocitinib https://allsci.com/news/funding/shennon-biotechnologies-raises-usd-12m-to-advance/ AllScien 2026-09-16T08:26:35.022801Z Shennon raises USD 12m to advance three preclinical T-cell engagers https://allsci.com/news/strategic-financing/orvida-pharma-financing-secures-recordati-led/ AllScien 2026-09-16T08:16:28.381645Z Orvida secures Recordati-led financing for ontivatrep in rare genetic skin diseases